Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
NCT04735523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5350
Last updated 2023-08-01
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
- Venous Thromboembolism
Interventions
- DRUG
-
Dabigatran
Dabigatran dispensing claim is used as the exposure group
- DRUG
-
Warfarin
Warfarin dispensing claim is used as the reference group
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-22
- Primary Completion
- 2021-02-18
- Completion
- 2021-02-18
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
NCT04736719 ·Status: COMPLETED
-
Comparative Effectiveness and Safety Between Warfarin and Dabigatran
NCT03254134 ·Status: COMPLETED
-
Comparative Effectiveness of Oral Anticoagulants
NCT01847547 ·Status: COMPLETED
-
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
NCT02596230 ·Status: COMPLETED
-
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage
NCT02061748 ·Status: COMPLETED
-
Sequential Expansion of Comparative Effectiveness of Anticoagulants
NCT02081807 ·Status: COMPLETED
-
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
NCT02769078 ·Status: COMPLETED
-
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
NCT00808067 ·Status: COMPLETED ·Phase: PHASE3
-
The DARE Warfarin CER Study
NCT03271450 ·Status: UNKNOWN
-
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
NCT00262600 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
NCT00401414 ·Status: COMPLETED ·Phase: NA
-
The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage
NCT02043808 ·Status: COMPLETED
-
Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran
NCT03050138 ·Status: COMPLETED
-
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
NCT02111564 ·Status: COMPLETED ·Phase: PHASE3
-
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
NCT00558259 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
NCT02161731 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
NCT01210755 ·Status: COMPLETED ·Phase: PHASE4
-
Rivaroxaban Anticoagulation for Superficial Vein Thrombosis
NCT02123524 ·Status: COMPLETED ·Phase: PHASE3
-
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
NCT00621855 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
NCT02504216 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation
NCT03792152 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
NCT00291330 ·Status: COMPLETED ·Phase: PHASE3
-
Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
NCT02979561 ·Status: UNKNOWN ·Phase: PHASE4
-
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
NCT01499953 ·Status: COMPLETED ·Phase: PHASE3
-
Xarelto Regulatory Post-Marketing Surveillance
NCT01029743 ·Status: COMPLETED